By Nicholas Bryant
Friday 1st September 2000
|Text too small?|
|COUGH LOLLY: The ground-breaking research is believed to have isolated an anti-bacterial protein that can cure streptococcal throat infections|
Broking sources said the company, Blis Technology, is within weeks of being quoted on the secondary board of unlisted securities, alongside Mr Patterson's white-hot A2 Corporation.
A2's share price increased 4000% in four months based on reports the company had isolated a milk protein in cows, A1, that increased the incidence of heart disease and diabetes.
The company is hoping to gain exclusive rights to milk products produced by "A2" cows which lack the troublesome protein.
But sources said Blis Technology has the potential to be even bigger than A2 as it is believed to have discovered a cure for an ailment that affects practically everybody - a sore throat.
Blis is an acronym for bacteriocin-like inhibitory substances.
Its exclusive technology, developed by a group of local scientists, focuses on a naturally occurring organism called salivaricin B.
The ground-breaking research is believed to have isolated an anti-bacterial protein that can cure streptococcal throat infections.
The market for strep-throat cures is huge, but most such conditions are receptive to treatment with penicillin-based antibiotics.
Doctors canvassed for their opinion of Blis's potential said it was obviously huge, but little could be ascertained without seeing the science.
"It sounds like quite a breakthrough, more along organic lines than traditional medicine, like the bug that kills the fruitfly in the orchard," one said.
Sources said Blis Technology was actively pursuing commercial possibilities of its discovery and was already negotiating with multinational firms.
International patent applications are also believed to have been lodged.
The prospect is understood to have been so promising among Blis's investors, many of whom also own shares in A2, that its private float was four times oversubscribed.
No comments yet
Ryman warns NZ, Australia to take population ageing more seriously
MARKET CLOSE: NZ shares fall as US-China trade concerns weigh on markets; Ryman slips
NZ dollar stalled; US-China trade deal may be postponed
AFT Pharmaceuticals starts to hit its straps
Crown seeks US$100m from Tui operator; Prospector moving on
Pacific Edge goes back to shareholders for another $20m
Crown seeks $100m from Tui operator Tamarind
Ryman underlying annual profit may rise by up to 17%
NZ dollar eases on increasing US-China doubts, lack of news in Fed minutes
From dog tucker to top dog: economists ask how Northport can be Auckland’s best replacement